Volume 43, Issue 1 pp. 46-49
Concise report

Systemic photodynamic therapy in folliculitis decalvans

N. J. Collier

Corresponding Author

N. J. Collier

Dermatology Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, UK

Correspondence: Dr Nicholas J. Collier, Dermatology Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Stott Lane, Salford, Manchester, M6 8HD, UK

E-mail: [email protected]

Search for more papers by this author
D. Allan

D. Allan

Dermatology Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, UK

Department of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

Search for more papers by this author
F. Diaz Pesantes

F. Diaz Pesantes

Prosser White Dermatology Centre, Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, UK

Search for more papers by this author
L. Sheridan

L. Sheridan

Department of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

Search for more papers by this author
E. Allan

E. Allan

Department of Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

Search for more papers by this author
First published: 22 September 2017
Citations: 15
Conflict of interest: the authors declare that they have no conflicts of interest.

Summary

Folliculitis decalvans (FD) is classified as a primary neutrophilic cicatricial alopecia, and is estimated to account for approximately 10% of all cases of primary cicatricial alopecia.[] The role of dysfunctional immune activity and the presence of bacteria, particularly Staphylococcus aureus, appear pivotal. We describe a 26-year-old man with a 4-year history of FD that was recalcitrant to numerous systemic and topical therapies, whose disease was virtually cleared during a follow-up of 25 months following a course of treatment with systemic photodynamic therapy (PDT) using ultraviolet light (100–140 J/cm2) with porfimer sodium 1 mg/kg as monotherapy. This is the first report of the use of systemic PDT as a treatment for FD. Systemic PDT has potent antibacterial effects with little or no resistance. In addition, systemic PDT provides local immunomodulation and improved scar healing. Significant adverse effects following systemic PDT with appropriate aftercare are rare. This case demonstrates that systemic PDT is a useful therapy option in the treatment of recalcitrant FD.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.